DE
39
3
OKE
59
3
A
48
4
CF
35
2
LOW
61
5
NFLX
59
-2
MET
50
3
DO
69
9
AEP
56
3
JBHT
42
4
TAP
45
-5
BLK
61
3
MCO
74
4
DG
26
-2
HPE
17
5
AN
60
2
HPQ
67
4
MU
55
4
INTU
69
4
KEY
53
2
DE
39
3
OKE
59
3
A
48
4
CF
35
2
LOW
61
5
NFLX
59
-2
MET
50
3
DO
69
9
AEP
56
3
JBHT
42
4
TAP
45
-5
BLK
61
3
MCO
74
4
DG
26
-2
HPE
17
5
AN
60
2
HPQ
67
4
MU
55
4
INTU
69
4
KEY
53
2
Financhill
Back

Cellectis SA 10K Form

Buy
97

CLLS
Cellectis SA

Last Price:
3.05
Seasonality Move:
-4.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLLS News And Ratings

See the #1 stock for the next 7 days that we like better than CLLS

CLLS Financial Statistics

Sales & Book Value

Annual Sales: $755K
Cash Flow: $39.44M
Price / Cash Flow: 0
Annual Sales: $1.18
Price / Book: 2.54

Profitability

EPS (TTM): -1.78000
Net Income (TTM): $-101.07M
Gross Margin: $18K
Return on Equity: -100.3%
Return on Assets: -39.35%

Cellectis SA Earnings Forecast

Key Cellectis SA Financial Ratios

  • The Gross Profit Margin over the past 17 years for CLLS is 2.38%.
  • The Selling, General & Administrative Expenses for CLLS have been equal to 2,226.75% of Gross Profit Margin.
  • The Research & Development expenses have been 11,608.74% of Revenue.
  • The Interest Expense is -5.25% of Operating Income.
  • The Net Earning history of CLLS is -13,385.30% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Cellectis SA Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLLS
CUSIP: 15117K
Website: cellectis.com

Debt

Debt-to-Equity Ratio: 0.4
Current Ratio: 1.5
Quick Ratio: 1.46

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CLLS Technical Analysis vs Fundamental Analysis

Buy
97
Cellectis SA (CLLS) is a Buy

Is Cellectis SA a Buy or a Sell?

  • Cellectis SA stock is rated a Buy
    The current Cellectis SA [CLLS] share price is $2.99. The Score for CLLS is 97, which is 94% above its historic median score of 50, and infers lower risk than normal.